FLT3 and acute myeloid leukemia: This approach is so appealing that almost all patients with a relapsed AML are currently retested for FLT3 mutations [63], even if patients acquiring an FLT3 mutation at relapse represent a minority and its occurrence has been reported in less than 8% [64].